Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells.

Sickle cell disease (SCD) is characterized by a single point mutation in the seventh codon of the β-globin gene. Site-specific correction of the sickle mutation in hematopoietic stem cells would allow for permanent production of normal red blood cells. Using zinc-finger nucleases (ZFNs) designed to flank the sickle mutation, we demonstrate efficient targeted cleavage at the β-globin locus with minimal off-target modification. By co-delivering a homologous donor template (either an integrase-defective lentiviral vector or a DNA oligonucleotide), high levels of gene modification were achieved in CD34(+) hematopoietic stem and progenitor cells. Modified cells maintained their ability to engraft NOD/SCID/IL2rγ(null) mice and to produce cells from multiple lineages, although with a reduction in the modification levels relative to the in vitro samples. Importantly, ZFN-driven gene correction in CD34(+) cells from the bone marrow of patients with SCD resulted in the production of wild-type hemoglobin tetramers.

[1]  D. Gordenin,et al.  Chromosomal site-specific double-strand breaks are efficiently targeted for repair by oligonucleotides in yeast , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  P. Malik,et al.  Gene therapy for hemoglobinopathies: the state of the field and the future. , 2014, Hematology/oncology clinics of North America.

[3]  Shondra M. Pruett-Miller,et al.  Nuclease-mediated gene editing by homologous recombination of the human globin locus , 2013, Nucleic acids research.

[4]  K. Sullivan,et al.  Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  T. Delea,et al.  Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States , 2008, American journal of hematology.

[6]  Laurent Kiger,et al.  Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells , 2005, Nature Biotechnology.

[7]  Shondra M Pruett-Miller,et al.  High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases , 2011, Nature Methods.

[8]  Morgan L. Maeder,et al.  In Situ Genetic Correction of the Sickle Cell Anemia Mutation in Human Induced Pluripotent Stem Cells Using Engineered Zinc Finger Nucleases , 2011, Stem cells.

[9]  D. Greiner,et al.  Creation of “Humanized” Mice to Study Human Immunity , 2008, Current protocols in immunology.

[10]  K. Goncz,et al.  Small fragment homologous replacement-mediated modification of genomic beta-globin sequences in human hematopoietic stem/progenitor cells. , 2006, Oligonucleotides.

[11]  G. Serjeant.  The natural history of sickle cell disease. , 1982, Cold Spring Harbor perspectives in medicine.

[12]  Huimin Zhao,et al.  Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. , 2014, Biotechnology and bioengineering.

[13]  Matthew Darlison,et al.  Global epidemiology of haemoglobin disorders and derived service indicators. , 2008, Bulletin of the World Health Organization.

[14]  M. Sadelain,et al.  Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation. , 2014, Blood.

[15]  M. van der Burg,et al.  Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells , 2014, Nature.

[16]  Xiao-Jin Yu,et al.  Transient gene expression by nonintegrating lentiviral vectors. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  J. Stockman.  Proof of principle for transfusion of in vitro–generated red blood cells , 2013 .

[18]  P. Mali,et al.  Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. , 2011, Blood.

[19]  Michael L Kaufman,et al.  β-globin gene transfer to human bone marrow for sickle cell disease. , 2013, The Journal of clinical investigation.

[20]  P. Rouet,et al.  Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. , 1994, Molecular and cellular biology.

[21]  Catherine J. Wu,et al.  In mixed hematopoietic chimerism, the donor red cells win , 2011, Haematologica.

[22]  Cage S. Johnson,et al.  Outcome of Sickle Cell Anemia: A 4-Decade Observational Study of 1056 Patients , 2005, Medicine.

[23]  M. Warr,et al.  Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. , 2010, Cell stem cell.

[24]  F. Mavilio,et al.  Mechanisms of retroviral integration and mutagenesis. , 2013, Human gene therapy.

[25]  Jeffrey C. Miller,et al.  An unbiased genome-wide analysis of zinc-finger nuclease specificity , 2011, Nature Biotechnology.

[26]  Vanessa Taupin,et al.  Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo , 2010, Nature Biotechnology.

[27]  Jeffrey C. Miller,et al.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases , 2005, Nature.

[28]  D. Kohn,et al.  Integrase-defective lentiviral vectors as a delivery platform for targeted modification of adenosine deaminase locus. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[30]  Jérôme Larghero,et al.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia , 2010, Nature.